APEIRON Biologics AG, based in Vienna, Austria, is a biotech company with a focus on biological and immunological approaches to treat cancer. The company was founded by Professor Josef Penninger and became operational in 2006. Apeiron currently employs about 35 people and is led by a management team with strong background in drug development, especially in immuno-oncology.


Apeiron's lead project APN311, an antibody-based therapy to treat patients suffering from neuroblastoma (a rare childhood cancer) has completed clinical development and its first application for marketing authorization is under review.
See projects for the present status of Apeiron's portfolio.

 

  • 438 hits27 March 2017

    APEIRON Biologics receives green light for marketing approval of APN311 in the European Union

    APEIRON Biologics AG today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of dinutuximab beta (APN311; ch14.18/CHO) for immunotherapy of high risk neuroblastoma.

     Presseaussendung

     Press Release